The increase in medical complexity among patients hospitalized with heart failure (HF) may be reflected by an increase in concomitant noncardiovascular comorbidities. Among patients hospitalized with HF, the temporal trends in the prevalence of noncardiovascular comorbidities have not been well described.
H
eart failure (HF) is associated with significant morbidity and mortality and places enormous burden on healthcare systems. 1, 2 There is growing recognition that patients with HF have a large burden of noncardiovascular comorbidities which may increase the risk of mortality and decrease quality of life. [2] [3] [4] Among US Medicare beneficiaries, 40% of patients with HF had >5 noncardiovascular comorbidities, and these patients accounted for the majority of days spent in hospital. 5 In the European Society of Cardiology HF Pilot survey, among outpatients with chronic HF, 74% had at least 1 noncardiovascular comorbidity, and an increasing number of noncardiovascular comorbidities was associated with a greater risk of mortality. 6 There is a perception that patients hospitalized for HF are also becoming more medically complex. However, unlike chronic HF, there is limited information on the burden of noncardiovascular comorbidities in patients who are hospitalized for HF. In addition, the temporal trends in the noncardiovascular comorbidity profile and the impact of noncardiovascular comorbidities on outcomes among patients hospitalized with HF remain unexamined. Using data from the Get With The Guidelines-Heart Failure (GWTG-HF) registry, among patients hospitalized for HF, we assessed (1) The prevalence of noncardiovascular comorbidities within the entire GWTG-HF registry cohort; (2) the temporal trends in the prevalence of noncardiovascular comorbidities; (3) the association of noncardiovascular comorbidities with hospital length of stay (LOS), in-hospital mortality, and 30-day mortality.
METHODS

Study Population
Data for this analysis come from the American Heart Association's GWTG-HF registry and linked Medicare claims available for research from the Centers for Medicare & Medicaid Services. The GWTG-HF registry is an ongoing quality improvement registry for patients hospitalized with HF in the United States. Details of the registry have been described previously. 7 Patients are eligible to be included in the GWTG-HF registry if they are admitted or discharged with a diagnosis of HF. Registry patients were linked to Medicare data using indirect identifiers, as described and validated previously. 8 The Medicare data include institutional claims for inpatient hospitalizations and the associated denominator files from 2005 to 2014. The denominator files include information about demographics, Medicare eligibility and enrollment, and mortality. Quintiles is the data collection coordination center for the American Heart Association/American Stroke Association Get With The Guidelines programs.
The study population for the present analysis included all patients in the GWTG-HF registry from January 1, 2005, to December 31, 2014. Sites with <75% completeness on medical history panel were excluded. Patients admitted after 2014, missing the medical history panel, or missing body mass index (BMI) were excluded. In 2005, history of prior myocardial infarction was not captured under the medical history panel. Similarly, a history of coronary artery bypass grafting or history of percutaneous coronary intervention was not captured under the medical history until 2008. Overall, 207 984 patients from 409 hospitals were included in our initial analysis on inhospital prevalence of noncardiovascular comorbidities and in-hospital outcomes. Medicare fee-for-service beneficiaries aged ≥65 years with a linked GWTG-HF hospitalization for HF discharged between January 1, 2005, and December 31, 2014, were used to assess 30-day outcomes. In total, 73 878 Centers for Medicare & Medicaid Services-linked GWTG-HF patients were included in our follow-up analysis on postdischarge outcomes. If the patient had multiple hospitalizations in the GWTG-HF registry, the first hospitalization was used for the analysis on postdischarge outcomes.
Definition of Noncardiovascular Comorbidities
For the present study, we defined noncardiovascular comorbidities as any of the following: chronic obstructive pulmonary disorder (COPD) or asthma, anemia, diabetes mellitus, chronic kidney disease/renal disease, obesity (BMI ≥30 kg/m 2 ), and depression. The selection of these comorbidities are based on the availability of data collected with the GWTG-HF registry
WHAT IS NEW?
• This analysis of the US national Get With The Guidelines-Heart Failure registry demonstrates that among patients admitted in hospital with heart failure, the number of noncardiovascular comorbidities has increased significantly.
• Patients with an increased number of noncardiovascular comorbidities have a greater risk of inhospital death and are less likely to be to a nursing facility.
• Furthermore, patients with an increased number of noncardiovascular comorbidities have a greater risk of 30-day death, all-cause readmission, and heart failure readmission.
WHAT ARE THE CLINICAL IMPLICATIONS?
• The medical complexity of patients admitted in hospital, as reflected by the burden of noncardiovascular readmission, has significantly increased over time. The in-hospital environment presents an ideal opportunity time to address and optimize these comorbidities.
• A multifaceted, multidisciplinary team-based approach to improving the management of these complex patients by treating these comorbidities should be strongly considered.
• In-hospital initiation of therapies that can optimize these comorbidities may improve long-term outcomes and should be evaluated in well-powered prospective randomized controlled trials.
and prior analyses that have defined the most clinically relevant noncardiovascular comorbidities among patients with HF.
4,6,9
Outcomes
We assessed hospital LOS >4 days, in-hospital mortality, 30-day mortality (from admission), 30-day all-cause readmission (from discharge), and 30-day HF rehospitalization (from discharge).
Statistical Analysis
We described the baseline characteristics of the study population by the number of noncardiovascular comorbidities (0, 1, 2, or ≥3) using proportions for categorical variables and means with SDs or medians with quartiles for continuous variables, testing for differences between groups using χ 2 tests for categorical variables and Wilcoxon rank-sum tests for continuous variables. We evaluated for temporal change in comorbidities from 2005 to 2014. In addition, we tested for LOS >4 days and mortality differences between groups (with patients who have 0 noncardiovascular comorbidities as the reference) using logistic regression models. Covariates used in adjustment models included standard GWTG-HF adjustment variables: age, race, sex, medical history of atrial fibrillation, atrial flutter, hyperlipidemia, hypertension, peripheral vascular disease, coronary artery disease, prior myocardial infarction, stroke, history of HF, smoking, hospital characteristics, region, teaching, hospital size, and rural location. 10 The generalized estimating equation method with exchangeable working correlation structure was used to account for within-hospital clustering. Odds ratios (ORs) and 95% confidence intervals (CIs) for OR were presented. Most variables had low rates of missingness. For imputation, after the prior exclusions, missing for all covariates are <5%. Age and sex have 0 missing. Missing race was imputed to whitemost frequent category. Missing medical histories were imputed to no. Missing hospital characteristics were excluded without imputation.
Cox proportional hazards regression models were performed to evaluate the association between number of noncardiovascular comorbidities and 30-day outcomes. The median LOS in the entire population was 4 days (interquartile range, 3-7). We, therefore, use 4 days as a bench mark in assessing the impact of noncardiovascular comorbidities and LOS. Hazard ratios (HR) and 95% CIs for different levels of number of noncardiovascular comorbidities are provided (0 comorbidity as the reference group). Both unadjusted and adjusted analyses were performed. The standard GWTG-HF adjustment variables were included in the adjusted analysis and included age, white race, sex, history of atrial fibrillation, atrial flutter, hyperlipidemia, hypertension, peripheral vascular disease, coronary artery disease, prior myocardial infarction, stroke, prior history of HF, smoking, hospital characters of region, teaching, hospital size, and rural location. Changes in the number of comorbidities may be attributed to increased capturing of comorbidities in billing codes. To ascertain whether objective measures of disease have been increasing over time, we assessed for changes in the number of people in the different quartiles of BMI and estimated glomerular filtration rate over time. Also, given the overall prevalence of patients with high BMI in our data set, we assessed the relationship between obesity status on 30-day outcomes, by analyzing regression models only adjusting for BMI (BMI ≥30 kg/m 2 ). We report 95% CIs and use α=0.05 to establish statistical significance of tests. All tests were 2 sided. SAS version 9.4 (SAS Institute Inc, Cary, NC) was used for all analyses. The institutional review board of the Duke University Health System approved the study. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
RESULTS
Baseline Demographics
In the 207 984 patients within our study population, 82% (n=170 717) of patients had at least 1 noncardiovascular comorbidity. Overall, 18% (n=37 267) had 0 noncardiovascular comorbidities; 30% (n=62 599) had 1 noncardiovascular comorbidity; 27% (n=56 889) had 2 noncardiovascular comorbidities; and 25% (n=51 229) had ≥3 noncardiovascular comorbidities. The most common noncardiovascular comorbidity was diabetes mellitus (45%; n=93 852) followed by COPD/ asthma (32%; n=66 996).
There was a lower median age associated with patients with a greater number of noncardiovascular comorbidities, from 80 years of age in patients with 0 noncardiovascular comorbidities down to 71 years of age in patients with ≥3 noncardiovascular comorbidities (P<0.0001; Table 1 ). Patients with more noncardiovascular comorbidities also had more cardiovascular comorbidities, including hypertension, peripheral vascular disease, coronary artery disease, and prior history of HF. Patients had a lower admission brain natriuretic peptide associated with a higher number of noncardiovascular comorbidities. There was a higher median ejection fraction of patients with a greater number of noncardiovascular comorbidities, from 35% in patients with 0 noncardiovascular comorbidities up to 46% in patients with ≥3 noncardiovascular comorbidities (P<0.0001). Correspondingly, there was a greater prevalence of HF with preserved ejection fraction (defined as an ejection fraction ≥40%) associated with a greater number of noncardiovascular comorbidities: 44% in patients with 0 noncardiovascular comorbidities to 61% in patients with ≥3 noncardiovascular comorbidities. Similar trends are seen among Medicare beneficiaries (Table I in BMI indicates body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CABG, coronary artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; HFpEF, heart failure with preserved ejection fraction; IQR, interquartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; and TIA, transient ischemic attack.
*All comparisons of baseline characteristics between groups were statistically significant at P<0.05. †Reported as median with IQR.
there was a corresponding increase in patients with ≥3 noncardiovascular comorbidities (from 18% in 2005 to 29% in 2014; P<0.0001; Figure 1 ; Table II in . With regards to temporal trends in cardiovascular comorbidities, there were an increase in atrial fibrillation (32%-37%), hypertension (73%-84%), and dyslipidemia (35%-54%). However, history of coronary artery disease declined slightly (51%-49%), and peripheral vascular disease remained relatively unchanged (12%-13%). As reflected in Figure 1 , the number of patients with obesity has been rising while chronic kidney disease remains unchanged. Depression had the greatest relative increase over time (87%). The number of patients with elevated BMI also increases over time while estimated glomerular filtration rate remains unchanged (Table III in 
Impact of Noncardiovascular Comorbidities and Outcomes
LOS and in-Hospital Mortality
There was an increasing LOS based on the number of noncardiovascular comorbidities ( 
30-Day Mortality, All-Cause Rehospitalization, and HF Rehospitalization
Among Medicare beneficiaries (n=73 878), 9.5% of patients died within 30 days of the index HF hospitalization. Of those with 0, 1, 2, and ≥3 noncardiovascular comorbidities, respectively, 9.2%, 9.5%, 9.5%, and 10.3% of patients died within 30 days of admission from the index HF hospitalization. There was an increased risk of 30-day mortality, compared with patients with 0 noncardiovascular comorbidi- Figure 3 ). Similarly, compared with patients with 0 noncardiovascular comorbidities, the risk of 30-day all-cause and HF readmission increased with an increasing number of noncardiovascular comorbidities (Table 3) 
DISCUSSION
We evaluated for the prevalence of noncardiovascular comorbidities and for an association of number noncardiovascular comorbidities with LOS, in-hospital mortality, and 30-day mortality among patients enrolled in the GWTG-HF registry who were admitted in hospital for HF. Our analysis identified the following major findings: (1) Patients admitted to hospital with HF have a large burden of noncardiovascular comorbidities; (2) From 2005 to 2014, there has been a decline in the number of patients with 0 or 1 noncardiovascular comorbidity and an increase in the number of patients with ≥3 noncardiovascular comorbidities; (3) patients with a greater number of noncardiovascular comorbidities have increased risk of longer hospital LOS, in-hospital mortality, and 30-day readmission and mortality.
Our analyses of patients hospitalized with HF aligns with prior studies in chronic stable populations which have identified that patients with HF have a large burden of noncardiovascular comorbidities. In a study using data from 1999 of 122 630 older US Medicare patients, ≈40% of patients with HF had ≥5 noncardiovascular comorbidities, and >80% of all in-hospital days are attributed to this patient group. 5 Among 3226 outpatients with chronic HF in the European Society of Cardiology HF Pilot Survey, 26% had no comorbidity, Discharge home is compared with discharge to other healthcare facility, acute care facility, or hospice. CI indicates confidence interval; and OR, odds ratio. 30% had 1 comorbidity, 23% had 2 comorbidities, and 43% had ≥2 comorbidities. 6 Our analysis extends on prior work evaluating comorbidities in patients with HF by evaluating trends over a decade and across a nationwide sample of hospitals in the United States. Utilizing the GWTG-HF registry enables a simultaneous evaluation of both in-hospital and postdischarge outcomes. Among patients with a greater number of noncardiovascular comorbidities, we have demonstrated a greater LOS and decreased risk of being discharged home (Table 2) combined with an increased risk of 30-day all-cause rehospitalization, 30-day HF rehospitalization, and 30-day mortality (Table 3) . Our evaluation of outcomes across multiple stages of a patients journey, both during and after a HF hospitalization, reflects the how the burden of noncardiovascular comorbidities may significantly influence the trajectories of outcomes.
We identified that patients with an increased number of noncardiovascular comorbidities were younger while prior analysis suggested that chronic stable patients with a greater burden of noncardiovascular comorbidities were older. 5, 6, 11 Our findings likely reflects our study population; younger patients without noncardiovascular comorbidities would have a reduced risk of hospitalization. Furthermore, older patients with multiple noncardiovascular comorbidities may have an increased competing risk of death, 5, 6 and thereby would be less likely to be admitted in hospital for HF. A prior analysis of Medicare patients from 1998 to 1999 also suggested that older patients hospitalized for HF, compared with younger patients, have a reduced incidence of several cardiovascular and noncardiovascular comorbidities. 12 In our study, despite the decreasing age seen with an increasing number of noncardiovascular comorbidities, the ejection fraction increased, and the proportion of patients with HF with preserved ejection fraction increased. Although prior studies in chronic stable HF population demonstrated that patients with HF with preserved ejection fraction do not have a significantly increased number of noncardiovascular comorbidities compared with heart failure with reduced ejection fraction, 6 a systematic review identified that overall, patients with HF with preserved ejection fraction have an increase burden of many noncardiovascular comorbidities. 4 The finding of reduced N-terminal pro-B-type natriuretic peptide levels with an increased number of noncardiovascular comorbidities may reflect the increased BMI and lower age seen these patients. 2, 13 Our analysis identified that diabetes mellitus was the most common noncardiovascular comorbidity followed by COPD/asthma, a finding previously seen 14, 15 ; these results are not surprising given the strong prognostic association of diabetes mellitus and COPD with increased HF hospitalization. 16, 17 Conditions, such as COPD and anemia, may contribute to HF decompensation and ultimately lead to a hospitalization. 17 In addition, several noncardiovascular comorbidities may not be modifiable by HF therapies and may require a multidisciplinary approach to hospitalized HF care. CI indicates confidence interval. *Adjusted for age, white race, sex, medical histories of atrial fibrillation, atrial flutter, hyperlipidemia, hypertension, peripheral vascular disease, coronary artery disease, prior myocardial infarction, stroke, heart failure, smoking, hospital characters of region, teaching, hospital size, and rural location.
†Thirty-day from admission. ‡Among patients discharged alive.
Our results suggest that the comorbidity profile of patients hospitalized with HF has significantly changed over time; more patients have an increased burden of noncardiovascular comorbidities. These finding reflect the observation that patients hospitalized with HF seem to be more medically complex and have multiple comorbid conditions that often complicates management. This increase in complexity among patients over time has been demonstrated across a spectrum of cardiovascular disease states. 18, 19 In a single tertiary care referral center study of 2507 outpatients with advanced HF, from 1993 to 2010, there was an increase in the prevalence of noncardiovascular comorbidities, such as diabetes mellitus (from 26% to 31%) and obesity (as reflected by an increase in BMI from 26 to 28 kg/ m 2 ). 20 Despite this increasing complexity of patients, our results suggest that regardless of the number of noncardiovascular comorbidities, over time, the mean LOS has declined. Hospitalization represents an ideal time to optimize patient comorbidities 21 ; however, incentives and pressures to decrease LOS in US hospitals may have resulted in the observed decline in the overall LOS for patients admitted with HF. 22 As more medically complex patients with multiple noncardiovascular comorbidities are admitted in hospital for HF, the expectation to rapidly discharge these patients may lead to nonoptimization of their comorbidities. In our analysis, patients with a higher BMI have a reduced risk of outcomes, which reflects the obesity paradox. These results highlight that the increased risk of outcomes see in patients with increased number of comorbidities is not driven completely by BMI.
Prior analyses of registry data and clinical trials of patients hospitalized with HF have identified that individual noncardiovascular comorbidities, such as diabetes mellitus, renal impairment, and COPD, significantly increase LOS and in-hospital mortality. [23] [24] [25] An increase in the number of noncardiovascular comorbidities was associated with an increase in the prevalence of cardiovascular comorbidities which may have contributed to the worsened outcomes; however, in our analysis, the association between in-hospital and 30-day mortality with the number of noncardiovascular comorbidities was present despite multivariable adjustment that included cardiovascular comorbidities. Because patients with an increased number noncardiovascular comorbidities were younger, it is not surprising after adjustment with variables that included age, the risk of outcomes increased. There are likely complex and interdependent mechanisms that contribute to this increased risk of outcomes, including increased activation of renin-angiotensin-aldosterone pathways, requirement of therapies that may increase HF risk (such as thiazolidinedione in patients with diabetes mellitus), increased salt/fluid retention (in renal insufficiency), and increased right ventricular strain (in patients with COPD and obesity).
3 Furthermore, the rates of HF readmission varies from 6.5% to 6.8% based on the number of noncardiovascular comorbidities; in comparison, the all-cause readmission rates ranges from 17% to 23.7%, suggesting that non-HF readmission form the major burden of readmission. Strategies to optimize and treat the growing burden of noncardiovascular comorbidities will be required and should be included in the delivery of in-hospital HF care pathway. Whether such strategies may improve outcomes remains to be determined in prospective trials.
Limitations
The GWTG-HF program is voluntary and may not represent the total population of patients with HF in the United States. Despite multivariable analyses, residual confounding may account for some of these observations. The comorbidities assessed are limited to those entered into the GWTG-HF case report form and likely underrepresents the burden of comorbidity in patients with HF. Although increased coding of comorbidities is a possible explanation for the increased number of comorbidities we are seeing over time, we have also demonstrated an increase in the objective measures of disease severity, such as increasing BMI over time. We did not have data on other comorbidities, such as sleep apnea, and there may have been other noncardiovascular comorbidities that could have been assessed; however, we focused on a limited list of relevant noncardiovascular comorbidities that have been identified in prior literature as being most relevant in patients with HF. The specific causes of death were not available. Potentially, our results may also reflect that the threshold to admit patients may have changed over the years and that patients are more sicker, and who likely have a greater number of comorbidities, when being admitted. Outcomes for 30-day mortality were limited to Medicare beneficiaries and may not reflect the overall GWTG-HF population; however, the trends in comorbidities in Medicare patients were similar to the overall population. The large number of patients observed may render some difference in observations as being statistically significant; however, these difference may not be clinically relevant.
Conclusions
Our results demonstrate that patients admitted in hospital with HF have become more medical complex over time: patients admitted to the hospital with HF have a large burden of noncardiovascular comorbidities, and the number of patients with multiple noncardiovascular comorbidities has significantly increased over time. These results have clinical implications because many noncardiovascular comorbidities contribute to worsening HF but will not be modified by HF-specific therapies. Patients with an increased number of noncardiovascular comorbidities have increased length of hospitalization and an increased risk of in-hospital and 30-day mortality, along with higher risk of 30-day all-cause and HF-specific readmission. Further research will be needed to evaluate the mechanisms, whereby noncardiovascular comorbidities complicate the management of patients hospitalized with HF. Furthermore, evaluating the specific causes of death among patients with multiple noncardiovascular comorbidities will be required to identify strategies that may reduce rates of mortality. Optimization of noncardiovascular comorbidities during HF hospitalization may represent an avenue to improve outcomes and warrants evaluation in prospective studies. Furthermore, these results highlight the need for multidisciplinary teambased care and improved coordination with primary care and other specialists to manage these complex patients.
